DNTH-103 is under clinical development by Dianthus Therapeutics and currently in Phase I for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Phase I drugs for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DNTH-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DNTH-103 overview
DNTH-103 is under development for the treatment of autoimmune diseases, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy and N.meningitidis infection. The drug candidate is a monoclonal antibody which is developed based on half-life extension technology. It acts by targeting complement C1s subcomponent. It is administered through intravenous and subcutaneous route. It is being developed based on YTE half-life extension technology,
Dianthus Therapeutics overview
Dianthus Therapeutics is a biopharmaceutical company that focuses on the development of next-generation complement therapies for the treatment of severe autoimmune diseases. The company’s primary activities focus on the research, development, and clinical testing of its lead antibody, DNTH103, that is designed to be self-administered through subcutaneous injections, offering a potential treatment option for patients with severe autoimmune disorders. Dianthus Therapeutics’ products are primarily aimed at treating neuromuscular disorders such as generalized myasthenia gravis (gMG), multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. The company operates in the biopharmaceutical industry, focusing on the development of therapies for autoimmune diseases. Dianthus Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of DNTH-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
